Metabolite-inspired compounds show promise for ulcerative colitis drug discovery

Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory activity in experimental ulcerative colitis in mice and human tissue, offering an underexplored drug discovery opportunity for this chronic inflammatory disease, according to a study led by researchers in the Institute for Biomedical Sciences at Georgia State University.

≈